Introduction
Psychiatric co-morbidity, often of a serious and disabling nature, has long been observed as a prevalent clinical feature among people living with multiple sclerosis (MS), and these potentially treatable comorbid disorders are important targets for detection [1, 2] . Depression has been the predominant focus of research into psychiatric co-morbidity in MS, with an approximate 50% lifetime prevalence reported [3] . Given the highly co-morbid nature of depression and anxiety in the general population, high rates of anxiety disorders in MS are not unexpected [3] [4] [5] [6] [7] . Co-morbid anxiety with depression in MS patients has also been associated with increased suicidal ideation, alcohol abuse, increased somatic complaints, and greater social dysfunction [4, 8, 9] . However, few studies have explored the prevalence of different subtypes of anxiety disorders, such as social anxiety disorder in individuals with MS.
In the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) [10] , social anxiety disorder is defined as excessive and persistent fear of social and performance situations in which there is the potential for embarrassment. These situations provoke intense anxiety symptoms, often experienced as somatic symptoms, and individuals may avoid social situations as a result. Social anxiety disorder can be particularly disabling with reduced likelihood of employment, social isolation, functional disability, and dissatisfaction with life and health. The highly co-morbid nature of social anxiety disorder with depression, panic disorder, and alcohol abuse is well established [11, 12] . In Canada, the national lifetime and 12-month prevalence of social anxiety disorder have been estimated at 8% and 3%, respectively [11] , whereas in the province of Nova Scotia, where the current study was based, the 12-month prevalence of social anxiety disorder has been estimated at 4.2% [13] .
Though strict adherence to the DSM-IV-TR does not allow for a diagnosis of social anxiety when the symptoms are considered limited to the general medical condition's social impact (i.e., "secondary social anxiety"), individuals with chronic physical or mental illnesses that have excessive social anxiety symptoms also have greater clinical and social morbidity [14] [15] [16] [17] . Persons with chronic neurological disorders including spasmodic torticollis (41.3%) [14] , Parkinson disease (29%) [17] , and essential tremor (22%) [18] were found to have a high prevalence of social anxiety when modified DSM criteria for social anxiety disorder were used.
One of the difficulties in using DSM nomenclature for establishing social anxiety disorder in a population with MS is the necessity of establishing substantial distress or dysfunction on the basis of the social anxiety symptoms alone. The symptoms that patients experience and their isolated impact can be difficult to determine, even with detailed diagnostic inquiry. Rather than rely on the lengthy diagnostic interviews necessary to establish the presence of social anxiety as a mental disorder, we chose instead to examine patients' self-reported symptoms of social anxiety. This was done to determine, in a cost-efficient manner, the severity and prevalence of clinically significant symptoms of social anxiety in a representative clinic sample. We also sought to examine the relations of social anxiety symptom severity with the presence of other common psychiatric comorbidities, with the severity of neurologic disability, and with self-reported health-related quality of life (HRQoL).
Materials and methods

Subjects
This study was conducted at the Dalhousie Multiple Sclerosis Research Unit (DMSRU) in Halifax, Nova Scotia, Canada. The DMSRU is the only specialist clinic serving people with MS in the province of Nova Scotia which has a population of approximately 940,000. A patient registry has been maintained at the DMSRU for the past 26 years and linkage with provincial health care records has determined that this registry includes over 80% of the persons with MS in Nova Scotia. Consecutive patients with a definite diagnosis of MS [19] , over age 18 who visited the clinic between May 1, 2006 and August 31, 2006 , and who provided written informed consent to participate in the study were recruited. Those whose cognitive capacity was considered likely to prevent them from understanding and filling out the questionnaires (i.e., Expanded Disability Status Scale [EDSS] Mental Functional System score ≥2 and/or clinician judgment) and those enrolled in clinical trials were excluded. The recruitment process is illustrated in Figure 1 . Approval for this study was obtained from the Capital Health Research Ethics Board.
Instruments
Patient age, gender, education, marital, and employment status as well as MS subtype (relapsing remitting, secondary progressive, or primary progressive) were collected from the DMSRU clinic database. Current neurological disability on the EDSS [20] and status (stable/improving or acute attack/progressive) was assessed at the time of the clinic visit. Patientreported HRQoL was assessed using the Mark 3 version of the Health Utility Index (HUI) [21] , a generic measure of health utility that represents an individual's health state on an interval scale from 0 (dead) to 1 (perfect health). The HUI is derived from ratings of hearing, speech, ambulation, vision, dexterity, cognition, emotion, and pain and has been shown to be a stable and valid measure of HRQoL in MS [22] .
We used the Social Phobia Inventory (SPIN) to assess symptoms of social anxiety [23] . The SPIN is a 17-item questionnaire available in the public domain that can be easily administered in a general medical practice. Its items evaluate the fear, avoidance, and physiological distress components of social anxiety. Severity of each symptom is rated on a scale from 0 to 4 such that the total score ranges from 0 to 68. A score of ≥19 has been found to distinguish persons with social anxiety from either healthy controls or psychiatric patients without social phobia [23] , including those with other forms of anxiety disorder [24] . It has demonstrated good internal consistency and reliability as well as responsiveness to treatment outcomes in psychiatric outpatients [23, 24] .
We used the 14-item Hospital Anxiety and Depression Scale (HADS) to assess symptoms of general anxiety (HADSA) and depression (HADSD) [25] . The anxiety subscale of the HADS does not distinguish subtypes of anxiety disorders and is weighed towards detecting generalized anxiety and panic symptoms rather than symptoms of social anxiety. Prior studies using the HADS with MS patients have used cutoff scores ranging from 8 to 11 [6, 7, 9, 26, 27 ], but we chose to use the originally suggested and more conservative cutoff score of ≥11 to identify the probable presence of depression and/or generalized anxiety disorder [25] .
The CAGE questionnaire was used to screen for potential co-morbid alcohol abuse. This four item screening tool was developed to detect problematic alcohol use and has been validated in ambulatory medical patients [28] . Cutoff scores ≥2 suggest the presence of alcohol abuse or dependence [29] .
Statistical analysis
Patients with a SPIN score of ≥19 were considered to have clinically significant symptoms of social anxiety. These high (social anxiety) and low (no social anxiety) SPIN groups were compared using chisquare analyses, t-tests, and Mann-Whitney U-tests for categorical, continuous, and ordered data, respectively, with a P value of <0.05 chosen to indicate statistical significance. Spearman's correlation coefficients, with pairwise exclusion of missing cases, were used to examine associations between the SPIN, HADSA, HADSD, EDSS, and HUI.
Results
In all, 277 patients met the inclusion criteria and were asked to participate in the study. Of these, 26 declined and 251 (91%) gave their consent to participate. Data from six (2%) participants were excluded from the analyses because they failed to complete two or more questions on the SPIN, leaving data from 245 in the study sample (Figure 1 ). For patients who met the inclusion criteria, there were no statistically significant differences in age, sex, EDSS, or classification of MS between those with (n = 245) and without (n = 32) complete data available for analyses.
The prevalence of clinically significant social anxiety symptoms in the study sample was 30.6% (n = 75), based on a SPIN cutoff score ≥19. Table 1 presents the sociodemographic and clinical characteristics of the low and high SPIN subgroups. Age, gender, MS duration, MS subtype, and neurological disability, as measured by the EDSS, did not differ between those with and without social anxiety. Those with significant social anxiety symptoms had on average 1 year less of education, although both groups were relatively well educated. A smaller proportion of those with social anxiety had stable MS at the time of the study. Patients with social anxiety were also less likely to be employed and more likely to be receiving disability pensions at the time of the study. Table 2 presents self-reported symptoms of depression and general anxiety as well as selfreported HRQoL.
Mean scores for symptoms of both depression (HADSD) and general anxiety (HADSA) were higher in those with social anxiety, whereas HRQoL, as measured by the HUI, was lower. Using HADS cutoff scores to identify patients with depression and general anxiety demonstrated high rates of co-morbid social anxiety with both general anxiety (36/49 = 73%) and depression (19/22 = 86%). However, when the SPIN was used to identify patients reporting significant social anxiety symptoms, their rates of co-morbid general anxiety (36/75 = 48%) and depression (25%) were relatively less. There was no association between alcohol abuse, as identified by subjects' responses to the CAGE, and the presence of significant social anxiety symptoms.
Associations between self-reported social anxiety symptoms, co-morbid psychiatric symptoms, HRQoL, and neurologic disability were also examined via correlations (Table 3) .
Moderate correlations were found between the SPIN and the HADSA, HADSD and HUI scores; whereas a low and statistically non-significant correlation was found between SPIN scores and ratings of neurologic disability on the EDSS. Nevertheless, greater neurologic disability (EDSS) was moderately associated with increased symptoms of depression (HADSD) and with reduced HRQoL (HUI).
Discussion
Just over 30% of our representative sample reported clinically significant symptoms of social anxiety. This point prevalence estimate is much higher than the estimated prevalence of social anxiety in the general and corresponding regional Canadian population [11, 13] and is in keeping with estimates of social anxiety reported in other chronic neurologic disorders [14, 17, 18] . However, our prevalence estimate is also much higher than other recently published prevalence estimates based on the use of the Structured Clinical Interview for DSM IV (SCID) (2.1% [4] , 2% [5] ). In part, this may reflect our inclusion of a consecutive series of clinic-presenting patients rather than only those with relapsing-remitting MS and mild disability [5] , but the lack of an association between neurologic disability and self reported social anxiety symptom severity argues against this. Our higher estimates may also reflect our use of a self report instrument that records symptoms of social anxiety regardless of their etiology, as opposed to a structured clinical interview based on DSM [10] . Because prevalence estimates of social anxiety in MS that have used the SCID are lower than the estimated population base rates established via self report of symptoms [11, 13] , as in our study, this explanation seems likely. Clearly, it can be argued that a cutoff score of ≥19 on the SPIN is overly sensitive and lacking in specificity for establishing the presence of social anxiety as a mental disorder in patients with MS, though this is not the case for general psychiatric patients [23, 24] . Nevertheless, the finding that over 30% of routinely presenting clinic patients met this cutoff signals the importance of social anxiety symptoms in MS patients. Moreover, our findings regarding co-morbid generalized anxiety and depression indicate that while the SPIN is indeed assessing the severity of social anxiety symptoms on a continuum, those reporting higher levels of these symptoms are experiencing distress. The lack of an association between severity of self-reported social anxiety symptoms and either physician-rated neurologic disability or the time from MS symptom onset might be considered an unexpected finding. However, social anxiety may be related to more specific neurologic symptoms (e.g., tremor, dysarthria, bowel and bladder dysfunction) that are likely to lead to anxiety in social situations. Social anxiety in persons with MS may also be associated more with the anticipated or perceived unpredictability of symptoms rather than with persistent disability and reduced ambulation. Our finding that proportionally fewer patients with social anxiety had stable MS at the time of the study is consistent with this possibility as is the previously reported association of general anxiety with MS exacerbations [30] . Further longitudinal studies will be needed to determine whether symptoms of social anxiety are related to changes in neurologic disability as well as the possible causal relations between specific MS symptoms and social anxiety.
Greater social anxiety symptom severity was also associated with poorer self-reported HRQoL, as in general population studies [11, 12] . Although we did not find an association between social anxiety and neurological disability, we did confirm our previously reported association between the EDSS and HUI [22] . Thus, our current findings indicate that social anxiety and neurologic disability each make significant but independent contributions to selfreported HRQoL for patients with MS. Greater comorbid general anxiety and depression among those patients with MS in our sample reporting significant social anxiety symptoms is also consistent with general population studies [12] . Although our prevalence estimate of social anxiety was higher than that of either general anxiety or depression, it is difficult to make direct comparisons and draw meaningful conclusions when different self report scales were used to obtain them. Though some studies have suggested that social anxiety may precede other psychiatric co-morbidities in the general population [11, 15] , our cross-sectional study could not address this possibility.
Importantly, alcohol abuse, as measured with CAGE, was not significantly higher in the social anxiety group and no more prevalent in our MS sample than in the general Canadian population when measured by the same instrument [31] . Alcohol abuse has been associated with social anxiety in general population studies [11, 32] , and it has been suggested to reflect alcohol use in high risk situations by socially anxious people, rather than increased consumption [33] . Although our findings could reflect insensitivity of the CAGE for socially anxious individuals, it may also be that alcohol use does not serve to manage the symptoms of social anxiety in persons with MS and that its use may exacerbate those MS symptoms that lead to social anxiety for some.
As noted above, one limitation of our study is its cross-sectional design which limited our ability to make causal inferences from associations. Another limitation is our lack of a DSM-based case finding method for establishing the presence or absence of social anxiety as a mental disorder according to standardized psychiatric nomenclature. Our aim, however, was to first determine whether social anxiety symptoms represent a clinically significant issue in a study sample representative of clinic-attending patients with MS. Clinically significant symptoms of social anxiety were highly prevalent and were present in almost one third of our sample. Social anxiety symptom severity was associated with generalized anxiety, depression, and self-reported HRQoL, but not with severity of neurologic disability or disease duration. Though often unrecognized and untreated, social anxiety is potentially treatable. Our findings suggest that social anxiety symptoms contribute to the overall morbidity of patients with MS and that their treatment may improve the quality of life of a significant proportion of people living with MS. Further study of the causes, optimal screening methods, and potential treatments of social anxiety symptoms in patients with MS is warranted and greater awareness and routine systematic inquiry about symptoms of social anxiety should be considered an important component of comprehensive care for persons with MS.
